Source: International Congress 2016 – Emerging concepts in lung disease pathogenesis
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Argyris Tzouvelekis (New Haven, United States of America), Argyris Tzouvelekis, Guoying Yu, Jose Herazo-Maya, Tony Woolard, Yi Zhang, Hojin Lee, Patty Lee, Erica Herzog, Anton Bennett, Naftali Kaminski. SH2 domain-containing phosphatase-SHP-2 is a novel anti-fibrotic regulator in pulmonary fibrosis. Eur Respir J 2016; 48: Suppl. 60, 4979

Member's Comments

No comment yet.

Related content which might interest you: Mast cells and fibroblasts work in concert to aggravate pulmonary fibrosis: Role of transmembrane SCF and PAR-2/PKCalpha/Raf-1/p44/42 signaling pathway Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities Year: 2013 Does apoptosis evasion only affect fibroblasts from idiopathic pulmonary fibrosis? Source: Annual Congress 2013 –Cell signalling and inflammation: what's new in 2013? Year: 2013 Increased fibrinolytic mediators in IPF as potential contributors to pulmonary fibrosis and vascular remodeling Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 Role of midkine in idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view Year: 2013 The ratio AGE/RAGE is increased in idiopathic pulmonary fibrosis Source: International Congress 2015 – Connective tissue disorders Year: 2015 Tranilast inhibits pulmonary fibrosis by suppressing TGFbeta-mediated extracellular matrix protein production Source: Annual Congress 2013 –Diffuse pulmonary fibrosis Year: 2013 Proteasome function in lung fibrosis Source: Annual Congress 2013 –Growth factors at the crossroads of acute and chronic inflammation Year: 2013 Fibulin-1 is a novel biomarker of disease severity in pulmonary fibrosis Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities Year: 2013 Club cell secretory protein-CC16 is increased in idiopathic pulmonary fibrosis Source: International Congress 2016 – ILD pathogenesis Year: 2016 Role of MUC1 in idiopathic pulmonary fibrosis Source: International Congress 2016 – ILD pathogenesis Year: 2016 The immunomodulatory effect of protein S in pulmonary fibrosis Source: Annual Congress 2013 –Diffuse pulmonary fibrosis Year: 2013 Role of JAK2/STAT3 pathway in vascular function of pulmonary fibrosis patients Source: International Congress 2015 – Pulmonary hypertension: promising small molecules Year: 2015 Novel biomarkers in bleomycin-induced pulmonary fibrosis Source: Annual Congress 2013 –Diffuse parenchymal lung disease II Year: 2013 IGFBP-2 a new interesting target in IPF Source: International Congress 2016 – ILD pathogenesis Year: 2016 Role of dendritic cells in pulmonary fibrosis in mice Source: International Congress 2016 – ILD: from the bench to the bedside Year: 2016 The role of extracellular vesicles in phenotypic alteration of lung cells in pulmonary fibrosis Source: Annual Congress 2013 –The role of hormones and cytokines in lung injury Year: 2013 The effect of dasatinib, a novel tyrosine kinase inhibitor, on the regression of pulmonary fibrosis in mice Source: International Congress 2014 – New and old players in fibrotic lung disease Year: 2014 Serum IGFBP2 as a marker of idiopathic pulmonary fibrosis Source: International Congress 2015 – Interstitial lung diseases II Year: 2015 Serum surfactant protein D may predict the effect of pirfenidone in idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities Year: 2013 Plasma protein signature of idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2013 –Translational research to bridge the need within clinical decision making Year: 2013